H.C. Wainwright lowered the firm’s price target on Biora Therapeutics to $50 from $65 and keeps a Buy rating on the shares. The analyst believes the shares “are approaching a critical tipping point on both the data and business development fronts.” The firm reduced the price target following the recent conversion of part of Biora’s debt to equity and issuance of 16.6M in common shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIOR:
- Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
- Biora Therapeutics submits IND application to FDA for BT-600 program
- Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure
- Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
- Biora Therapeutics achieves performance targets for BioJet platfor